Objective: Asymmetric dimethylarginine (ADMA) is an endogenous nitric oxide synthase inhibitor and a marker of vascular endothelial damage. Angiotensin-converting enzyme inhibitor and angiotensin II receptor blocker (ARB) are reported to reduce the serum ADMA level. Our group administered either ARB or calcium antagonist to patients after cerebral infarction and discussed the ADMA changes observed.
Introduction
Endothelium-derived nitric oxide (NO) is a potent vasodilator and endogenous anti-atherosclerotic molecule. NO is synthesized from L-arginine by NO synthase (NOS) in endothelium.
Asymmetric dimethylarginine (ADMA) is an endogenous NOS inhibitor. The serum ADMA level is reportedly higher in diseases known to promote vascular endothelial dysfunction such as hypertension, dyslipidemia and diabetes mellitus. The ADMA level is also associated with cerebral infarction 1 .
Hypertension is the strongest risk factor for cerebral infarction. However, no specific antihypertensive is confirmed to be significantly effective in preventing relapses of cerebral infarction. We find in the literature that angiotensin II receptor blocker (ARB) is significantly more effective than calcium antagonist in suppressing cerebral infarction relapse 2 .
Angiotensin-converting enzyme (ACE) inhibitor and ARB are reported to be effective in reducing ADMA 3 6 .
There is no report, however, confirming reduced ADMA levels in response to ARB treatment in hypertensive patients with cerebral infarction in the chronic stage.
In this study we administered candesartan cilexetil (ARB) or amlodipine (calcium antagonist) to hypertensive patients in the chronic stage of cerebral infarction and investigated the effect of the agents on serum ADMA levels.
Materials and Methods
The subjects were hypertensive patients in the chronic 
Results
The . 1 ). There was no significant difference between the groups in the change of systolic blood pressure (P=0.500) or diastolic blood pressure (P= 0.770). (Fig. 2-a) . Meanwhile, ADMA levels in the amlodipine group were 0.45 0.08 nmol/mL (before treatment) and 0.49 0.08 nmol/mL (after treatment), showing no significant change between before and after treatment (P=0.290) (Fig. 2-b) .
Discussion
We administered candesartan cilexetil and amlodipine to By what mechanism does ARB reduce serum ADMA levels? ARBs and ACE inhibitors are reported to reduce ADMA levels independent of depressor effect 5, 6 . Our find- Fig. 1 Changes of blood pressure before and after treatment in the candesartan group and amlodipine group There were no significant differences between the candesartan group and amlodipine group in the changes of blood pressure before and after treatment. (Unpaired T-test) Systolic BP=systolic blood pressure, Diastolic BP=diastolic blood pressure Changes of BP=changes of blood pressure before and after treatment NS=not significant 
